FAQs

blank

hidden

What is Personalized Medicine?

Personalized medicine uses information specific to the unique patient to inform treatment decisions that are most optimal for that individual.

Personalized medicine presents a deeper understanding of a patient’s disease, opens the door to enhanced accuracy in treatment selection, enables avoidance of less effective treatments, and presents the opportunity for improved clinical outcomes for the individual patient.

What is the difference between CANscript and typical genomic tests?

Genomic tests detect genes and gene abnormalities to classify a patient into a defined population, and recommend treatments based on the experiences of other members of the same population.

CANscript is different. CANScript uses the patient’s own biology by replicating their unique tumor microenvironment to predict treatment response specific to that individual patient. By evaluating the unique patient, rather than a population in which an individual patient may or may not respond to given treatments, CANscript predictions offer true personalization resulting in high correlation to actual clinical outcomes.

What is a tumor microenvironment?

The tumor microenvironment (TME) is the complex, cellular environment where a tumor lives, and includes the tumor vasculature, blood vessels, stroma, extracellular matrix, anti-tumor immune cells, and more. Each component of the tumor microenvironment is interrelated, and its comprehensive biological composition effects the tumor, how it grows, and how it responds to treatment.

What actionable information does CANscript provide?

CANscript delivers powerful predictions which can help determine the effectiveness of tested treatments for an individual patient. CANscript classifies each tested treatment as likely to produce a response or likely to be less effective, aiding in more informed and personalized treatment selection.

Because the treating physician selects the treatments to be tested by CANscript, treatments with the highest predictions for improved clinical outcomes should be readily available to administer. This enables the individual patient to receive the treatment most likely to produce results, precisely when that patient is in need of treatment.

What tumor types can be tested with CANscript?

The CANscript algorithm has been trained and validated across a range of tumor types, including Non-Small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer, Ovarian Cancer, and Colorectal Cancer.

What treatments can be tested with CANscript?

The CANscript algorithm has been validated in multiple drug classes, and CANscript is able to test single agents and combination therapies.

How soon will CANscript deliver results?

CANscript delivers results in 7 days from receipt of patient specimen at the Mitra laboratory.

What are the specimen requirements to run CANscript?

To successfully replicate the tumor microenvironment, CANscript requires fresh, unprocessed live tumor tissue and a blood sample.

  1. 10 ml pre-biopsy blood
  2. Biopsy tissue, shipped to arrive at Mitra within 24 hours of procedure
    • Non-necrotic
    • Non-fatty
    • Clot-free

Core Biopsy:

  • 18 gauge
  • Each core 1 cm long
  • 1 core more than total treatments to be tested

Excisional Biopsy:

  • 100 – 200 mm3 section
What is a CANscript M-Score?

A CANscript M-Score is a score between 1 and 100 which indicates the predicted treatment response. The higher the score, the more likely the treatment is to produce a clinical response.

  • An M-Score of 25 or lower indicates that a treatment is likely to be less effective.
  • An M-Score of 26 or higher indicates that the treatment is likely to produce a response.
Bitnami